SARVARI YELLAPRAGADA to Multiple Myeloma
This is a "connection" page, showing publications SARVARI YELLAPRAGADA has written about Multiple Myeloma.
Connection Strength
2.217
-
Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450.
Score: 0.665
-
Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020 04 28; 4(8):1643-1646.
Score: 0.603
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
Score: 0.192
-
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710.
Score: 0.181
-
Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514.
Score: 0.166
-
Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
Score: 0.164
-
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 06 13; 133(24):2615-2618.
Score: 0.140
-
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
Score: 0.104